Intubation

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

Retrieved on: 
Wednesday, March 27, 2024
Principal, Annual, Fungal infection, TFF, COVID, Intubation, International Society, Part, Patient, Biomarker, IPA, Spirometry, EAP, Mortality, Lung transplantation, Microsoft Access, Potential, Safety, Kidney, Heart, Pharmaceutical industry

FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced updated data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

Key Points: 
  • “Based on the totality of these clinical data, we believe TFF TAC and TFF VORI have the potential to establish a new and significantly improved form of delivery for these two life-saving medicines.
  • The updated safety and efficacy data are based on the cutoff date of March 8, 2024.
  • The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity.
  • The Company will host a conference call today at 4:30 pm Eastern Time, to discuss updated data for the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

CHLA Researchers Find That Length of Opioid Treatment for Hospitalized Infants Differs by Institution and Geography

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Research, Pharmaceutical, Family, Consumer, Hospitals, Children, Science, Surgery, Baby, Maternity, Other Science, Health, JAMA Network Open, Ventricular septal defect, Risk, Infant, Prescription, MD, Methadone, MSHS, Hydromorphone, Morphine, Multimedia, Paper, Policy, Intubation, Fentanyl

View the full release here: https://www.businesswire.com/news/home/20240312681130/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240312681130/en/
    In a study published in JAMA Network Open, researchers at Children’s Hospital Los Angeles found the opioid treatment that critically ill, hospitalized infants received depended on their location.
  • The length of time the infants were prescribed opioids differed by geographic region across the U.S.— the Northeast, South, Midwest or West.
  • “Additionally, prolonged opioid exposure in high-risk hospitalized infants has been implicated in worsening neurodevelopmental outcomes,” Dr. Keane says.
  • During their hospital stay, 76% of infants were prescribed opioids such as fentanyl, morphine and hydromorphone, and about 8% received methadone.

Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

Retrieved on: 
Wednesday, April 3, 2024
ART, OXY, Annual report, Unitary state, Risk, Patient, Coma, Abdomen, Research, Meconium, Meconium aspiration syndrome, Human, Congenital diaphragmatic hernia, Intubation, Pharmaceutical industry

Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.

Key Points: 
  • Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.
  • Inspira aims to explore how this potential additional application of the INSPIRA ART100 device to provide neonates with vital respiratory support could replace the currently used mechanical ventilators.
  • "Inspira is dedicated to pushing the boundaries of medical technology to save and improve lives," remarked Dagi Ben-Noon, CEO of Inspira Technologies.
  • The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.

Inspira™ Technologies Reports Full Year 2023 Financial Results

Retrieved on: 
Monday, March 25, 2024
ART, OXY, Research, Annual report, Unitary state, IIA, Intubation, Risk, Patent, Patient, Coma, S&M, Hospital, G&A, Coagulation, Insurance, D&O, Carbon, Human, Hemolysis, Marketing, FDA, Total, Food, Pharmaceutical industry

RA'ANANA, Israel, March 25, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023.
  • With our ground-breaking technologies and products, we are not just looking at the horizon but actively shaping it, leveraging our proprietary technologies to make a meaningful impact."
  • Total operating expenses decreased to US$12,133,000 in of the year ended December 31, 2023, from US$14,893,000 in the same period of 2022.
  • As of December 31, 2023, financial liabilities at fair value totaled US$1,470,000 compared to US$26,000.

Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

Retrieved on: 
Monday, March 18, 2024
ART, OXY, Annual report, Unitary state, Risk, Patient, Coma, Research, Sale, Human, Ministry, Blood, Intubation, Medical device

"The enthusiastic support from local key-opinion leaders highlights the excitement surrounding our technology, setting the stage for its global journey.

Key Points: 
  • "The enthusiastic support from local key-opinion leaders highlights the excitement surrounding our technology, setting the stage for its global journey.
  • This method is expected to significantly reduce complications associated with traditional ventilation methods, shorten hospital stays and potentially save lives.
  • The INSPIRA™ ART (Gen 2) device is the culmination of extensive research and development efforts by the team at Inspira.
  • The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.

Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

Retrieved on: 
Tuesday, March 12, 2024
ART, OXY, Annual report, Unitary state, Pressure, Risk, Patent, Inflammation, Patient, Coma, Carbon, Human, Bleeding, Hemolysis, Blood, Intubation, Medical device

The performance of the VORTX™, tested according to a regulatory guideline, was found to meet 100% of blood oxygenation requirements at various blood flow rates.

Key Points: 
  • The performance of the VORTX™, tested according to a regulatory guideline, was found to meet 100% of blood oxygenation requirements at various blood flow rates.
  • A significant leap forward in the development of safer, more effective medical devices designed to minimize patient risk and improve clinical outcomes.
  • The advanced experiments demonstrated the primary performance of the VORTX™ by collecting data on oxygenation, carbon dioxide removal, and pressures across the device during blood use.
  • This stands in stark contrast to membrane-based devices, which typically experience significant pressure drops, leading to potential damage to the patient's blood.

Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days

Retrieved on: 
Monday, March 4, 2024
Collection, Aggregation, Coma, Sensor, Risk, FDA, Blood, Physician, Food, Unitary state, Annual report, Nursing care plan, ART, Second generation, Food and Drug Administration, Patient, OXY, HYLA, Intubation, Human

The INSPIRA ART (Gen 2) is designed to utilize adaptive oxygenation technology, leveraging the proprietary HYLA™ blood Sensor and VORTX™ Orbiting Blood Oxygenation, to delivery oxygen straight into the blood.

Key Points: 
  • The INSPIRA ART (Gen 2) is designed to utilize adaptive oxygenation technology, leveraging the proprietary HYLA™ blood Sensor and VORTX™ Orbiting Blood Oxygenation, to delivery oxygen straight into the blood.
  • The proprietary core technology has undergone a series of testing in a variety of settings, with the results being collected and analyzed.
  • The results refer to the INSPIRA ART (Gen 2), with the new core technology potentially being suitable for replacing current solutions in medical markets dominated by leading medical device companies.
  • The Company plans to announce the primary results around the core blood oxygenation technology of the INSPIRA ART (Gen 2) within days.

Inspira™ To Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone

Retrieved on: 
Tuesday, February 27, 2024
Coma, Risk, Unitary state, Annual report, ART, Patient, Eastern Time Zone, OXY, Intubation, Human

Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, announced today that the Company President, Director and co-founder, Mr. Joe Hayon, will present an Investor Presentation and announce the Company's next major milestone.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, announced today that the Company President, Director and co-founder, Mr. Joe Hayon, will present an Investor Presentation and announce the Company's next major milestone.
  • The conference call is to be held at 9:00am Eastern Time on Monday, March 4, 2024.
  • To attend the conference call, please enter: link
    Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena.
  • For example, the Company is using forward-looking statements when it discusses the expected release of the investor presentation and announcement of its next major milestone.

Inspira™ Announces Breakthrough Update: Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements

Retrieved on: 
Tuesday, February 27, 2024
Coma, Risk, FDA, Blood, Unitary state, Patent, Annual report, ART, Patient, OXY, HYLA, Intubation, Human, Medical device

Three breakthrough patents have been approved by the United States Patent and Trademark Office ("USPTO") and an additional three patent applications are pending at the USPTO for certain core technologies.

Key Points: 
  • Three breakthrough patents have been approved by the United States Patent and Trademark Office ("USPTO") and an additional three patent applications are pending at the USPTO for certain core technologies.
  • To date, the Company has signed $546 million in pre-conditioned summary distribution agreements, subject to regulatory approvals and authorizing authorities.
  • We vision the INSPIRA ART is expected to changing the medical landscape, with the VORTX orbiting blood oxygenation delivery system.
  • The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels.

Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies

Retrieved on: 
Thursday, February 22, 2024
Coma, Risk, Blood, Unitary state, Annual report, Carbon, ART, Element, Patient, OXY, Tissue, Intubation, Research, Human, Hemolysis, Medical device

This platform has played, and will continue to play, a vital role in advancing the development of our HYLA Blood Sensor and VORTX Orbiting blood oxygenation delivery system, which are the core technologies of the Inspira ART500.

Key Points: 
  • This platform has played, and will continue to play, a vital role in advancing the development of our HYLA Blood Sensor and VORTX Orbiting blood oxygenation delivery system, which are the core technologies of the Inspira ART500.
  • Using unique methods and equipment, our team of scientists has the ability to simulate human blood conditions based on a predefined medical profile.
  • This platform allows Inspira Technologies to control the blood parameters over a wide range, allowing it to test the efficacy and accuracy of its technologies in key scenarios, such as simulating the blood parameters of patients who may suffer from acute medical conditions.
  • The Chief Technology Officer of Inspira Technologies, Dr. Daniella Yeheskely-Hayon, stated: "Inspira Technologies focuses on developing advanced blood monitoring and oxygen delivery technologies through its high-end testing platforms which allows it perform wider range-controlled testing while minimizing the need to perform in vivo animal testing."